Skip to main content
. Author manuscript; available in PMC: 2024 Oct 19.
Published in final edited form as: Pharmacol Ther. 2021 Mar 31;225:107844. doi: 10.1016/j.pharmthera.2021.107844

Table 1.

Clinical trials of different FLT3 inhibitors including the FDA approved TKIs (midostaurin and gilteritinib)a.

Drug aChemical structure Clinical trial ID Sample size (year age) Intervention/Treatment Efficacy Phase Ref.
Midostaurin graphic file with name nihms-2026888-t0004.jpg NCT00651261 717 (18–59) Cytarabine and daunorubicin plus, midostaurin versus placebo in newly diagnosed AML patients Median OS: 74.7 months, Midostaurin group; 25.6 months, Placebo group Median EFS: 8.2 months (95% CI, 5.4 to 10.7), midostaurin group; 3.0 months (95% CI, 1.9 to 5.9), placebo group III (Stone et al., 2017)
Gilteritinib (ASP2215) graphic file with name nihms-2026888-t0005.jpg NCT02421939 371(18 and older) Gilteritinib (ASP2215) versus salvage chemotherapy in R/R AML patients harboring FLT3 mutation Median OS: 9.3 months, Gilteritinib; 5.6 months, Chemotherapy group Median EFS: 2.8 months, gilteritinib group; 0.7 months, chemotherapy group III (Perl et al., 2019)
Sorafenib graphic file with name nihms-2026888-t0006.jpg NCT00893373 276
(18–60)		 Sorafenib added to standard primary therapy in newly diagnosed AML patients median EFS 9 months, placebo group versus 21 months, sorafenib group; 3-year-EFS of 22%, placebo group versus 40%, sorafenib group II (Rollig et al., 2015)
Lestaurtinib (CEP-701) graphic file with name nihms-2026888-t0007.jpg NCT00079482; 224(18 and older); Lestaurtinib (CEP-701) given in sequence with induction chemotherapy 29 patients with CR/CRp in the lestaurtinib arm and 23 in the control arm; No difference in OS between the 2 arms; No overall clinical benefit II (Levis et al., 2011)
ISRCTN17161961and (Knapper et al., 2017)
ISRCTN55675535 500(5 to 68) in patients with relapsed AML expressing FLT3 activating mutations; patients with newly diagnosed AML or high-risk myelodysplastic syndrome III (Knapper et al., 2017)
Quizartinib graphic file with name nihms-2026888-t0008.jpg NCT02039726 367(18 and older) Quizartinib Monotherapy vs. Salvage Chemotherapy Median OS: 6·2 months (5·3–7·2), quizartinib group; 4·7 months (4·0–5·5), chemotherapy group III (Cortes et al., 2019)
a

References of 2D structures in Table 1.

1. PubChem Identifier: CID 126565 (Lestaurtinib)

2. PubChem Identifier: CID 216239 (Sorafenib)

3. PubChem Identifier: CID 24889392 (Quizartinib)

4. PubChem Identifier: CID 49803313 (Gilteritinib)

6. PubChem Identifier: CID 9829523 (Midostaurin)